Improving experimental drug success rate and accelerating clinical development are top priorities for pharmaceutical and biotech companies. Careful and considered decision-making is essential early on in the process to minimise development time, manage a project’s costs and improve the probability of commercial success. Bruno Speder at SGS Clinical Research showcases how the use of modelling and simulation tools can be a very useful strategy to mitigate such risks and make better-informed decisions.